Jianxin Biosciences

Jianxin Biosciences (often referred to as Jianxing Biosciences) is a clinical-stage biotechnology company focused on developing innovative tumor-infiltrating lymphocyte (TIL) therapies for the treatment of solid tumors. Based in Hangzhou, China, the company leverages its proprietary platform to optimize the isolation, activation, and large-scale expansion of polyclonal, tumor-reactive T cells. Its lead candidate, JX-01, is an autologous TIL therapy currently in Phase 1/2 clinical trials for advanced solid tumors, including melanoma and non-small cell lung cancer. The company's pipeline also includes next-generation TIL therapies designed to overcome the immunosuppressive microenvironment of solid cancers. Jianxin Biosciences aims to provide personalized and potent cell therapies for patients who have exhausted standard treatment options.